Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | LSS | P48449 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25916636 | 0.80 | HTR2A (0.39) | LPLLIPGCHRM1CHRM2CHRM3 | |
| SCHEMBL17897342 | 0.78 | QDPR (0.54) | LPLLIPG | |
| SCHEMBL22448147 | 0.77 | LIPG (0.54) | LPLLIPGP2RX7 | |
| SCHEMBL12845155 | 0.76 | LIPG (0.53) | LPLLIPGP2RX7 | |
| SCHEMBL22448166 | 0.75 | LIPG (0.51) | LPLLIPGP2RX7 | |
| SCHEMBL10224311 | 0.73 | P2RX7 (0.53) | CHRNB2CHRNA4CHRM1CHRM2CHRM3 | |
| SCHEMBL12950949 | 0.73 | CHRNB2 (0.57) | CHRNB2CHRNA4LSSCHRM1CHRM2 | |
| SCHEMBL27024875 | 0.72 | CCNT1 (0.39) | LPLLIPG | |
| SCHEMBL24608995 | 0.72 | LIPG (0.83) | LPLLIPG | |
| SCHEMBL2707320 | 0.72 | LIPG (0.83) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |